Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biphozyl
- Development stage
- Phase 4
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Biphozyl is a phosphate-containing, calcium-free electrolyte solution used as a replacement fluid or dialysate in continuous renal replacement therapy (CRRT). It is specifically formulated for patients with acute kidney injury (AKI) who require phosphate supplementation or are undergoing regional citrate anticoagulation (RCA). Because Biphozyl lacks calcium, it prevents premature clotting in the extracorporeal circuit when citrate is used as an anticoagulant, while its phosphate content helps maintain normal serum phosphate levels and prevents CRRT-induced hypophosphatemia. The solution also contains bicarbonate to assist in the management of acid-base balance. It was developed by Baxter International and is now part of the Vantive Health portfolio.
- Brand names
- Biphozyl
Beyond the preview
Go deeper on Biphozyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biphozyl.